Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Positief BOM-advies voor pembrolizumab bij gemetastaseerd colorectaal carcinoom
feb 2021 | Immuuntherapie, Maag-darm-leveroncologie